Association between piperacillin/tazobactam use and acute kidney injury in critically ill patients : a retrospective multicentre cohort study
© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: Piperacillin/tazobactam is one of the most common antibiotics prescribed in the ICU and the combination of piperacillin/tazobactam with vancomycin has been associated with acute kidney injury (AKI) in critically ill patients. However, data on the risk of AKI with piperacillin/tazobactam, despite vancomycin co-exposure, are lacking.
OBJECTIVES: To investigate the association of piperacillin/tazobactam with AKI and renal replacement therapy (RRT) among adult ICU patients.
METHODS: We analysed data from patients included in two open access databases (MIMIC-IV and eICU). Critically ill patients who received piperacillin/tazobactam or cefepime (a cephalosporin with similar broad-spectrum activity to piperacillin/tazobactam) during their first ICU stay were eligible for the study. Marginal structural Cox models, accounting for time-fixed covariates and time-dependent covariates were performed. The primary outcomes were AKI and need of RRT.
RESULTS: A total of 20 107 patients were included, with 11 213 in the piperacillin/tazobactam group and 8894 in the cefepime group. Exposure to piperacillin/tazobactam was associated with AKI (HR 1.77; 95% CI 1.51-2.07; P < 0.001) and with need of RRT (HR 1.31; 95% CI 1.08-1.57; P = 0.005). Tests for interaction were not statistically significant for occurrence of AKI and RRT in the subgroup of patients exposed to vancomycin or not (P = 0.26 and P = 0.6, respectively).
CONCLUSIONS: In critically ill patients, exposure to piperacillin/tazobactam was associated with increased risk of AKI and with increased risk of RRT, regardless of combination therapy with vancomycin.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
---|---|
Enthalten in: |
The Journal of antimicrobial chemotherapy - 79(2024), 3 vom: 01. März, Seite 552-558 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Tomazini, Bruno Martins [VerfasserIn] |
---|
Links: |
---|
Themen: |
157044-21-8 |
---|
Anmerkungen: |
Date Completed 04.03.2024 Date Revised 04.03.2024 published: Print Citation Status MEDLINE |
---|
doi: |
10.1093/jac/dkae001 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM36743380X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM36743380X | ||
003 | DE-627 | ||
005 | 20240304232320.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240123s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1093/jac/dkae001 |2 doi | |
028 | 5 | 2 | |a pubmed24n1316.xml |
035 | |a (DE-627)NLM36743380X | ||
035 | |a (NLM)38252887 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Tomazini, Bruno Martins |e verfasserin |4 aut | |
245 | 1 | 0 | |a Association between piperacillin/tazobactam use and acute kidney injury in critically ill patients |b a retrospective multicentre cohort study |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 04.03.2024 | ||
500 | |a Date Revised 04.03.2024 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
520 | |a BACKGROUND: Piperacillin/tazobactam is one of the most common antibiotics prescribed in the ICU and the combination of piperacillin/tazobactam with vancomycin has been associated with acute kidney injury (AKI) in critically ill patients. However, data on the risk of AKI with piperacillin/tazobactam, despite vancomycin co-exposure, are lacking | ||
520 | |a OBJECTIVES: To investigate the association of piperacillin/tazobactam with AKI and renal replacement therapy (RRT) among adult ICU patients | ||
520 | |a METHODS: We analysed data from patients included in two open access databases (MIMIC-IV and eICU). Critically ill patients who received piperacillin/tazobactam or cefepime (a cephalosporin with similar broad-spectrum activity to piperacillin/tazobactam) during their first ICU stay were eligible for the study. Marginal structural Cox models, accounting for time-fixed covariates and time-dependent covariates were performed. The primary outcomes were AKI and need of RRT | ||
520 | |a RESULTS: A total of 20 107 patients were included, with 11 213 in the piperacillin/tazobactam group and 8894 in the cefepime group. Exposure to piperacillin/tazobactam was associated with AKI (HR 1.77; 95% CI 1.51-2.07; P < 0.001) and with need of RRT (HR 1.31; 95% CI 1.08-1.57; P = 0.005). Tests for interaction were not statistically significant for occurrence of AKI and RRT in the subgroup of patients exposed to vancomycin or not (P = 0.26 and P = 0.6, respectively) | ||
520 | |a CONCLUSIONS: In critically ill patients, exposure to piperacillin/tazobactam was associated with increased risk of AKI and with increased risk of RRT, regardless of combination therapy with vancomycin | ||
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Journal Article | |
650 | 7 | |a Cefepime |2 NLM | |
650 | 7 | |a 807PW4VQE3 |2 NLM | |
650 | 7 | |a Vancomycin |2 NLM | |
650 | 7 | |a 6Q205EH1VU |2 NLM | |
650 | 7 | |a Piperacillin, Tazobactam Drug Combination |2 NLM | |
650 | 7 | |a 157044-21-8 |2 NLM | |
700 | 1 | |a Besen, Bruno Adler Maccagnan Pinheiro |e verfasserin |4 aut | |
700 | 1 | |a Taniguchi, Leandro Utino |e verfasserin |4 aut | |
700 | 1 | |a Zampieri, Fernando Godinho |e verfasserin |4 aut | |
700 | 1 | |a Cavalcanti, Alexandre Biasi |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t The Journal of antimicrobial chemotherapy |d 1981 |g 79(2024), 3 vom: 01. März, Seite 552-558 |w (DE-627)NLM000017701 |x 1460-2091 |7 nnns |
773 | 1 | 8 | |g volume:79 |g year:2024 |g number:3 |g day:01 |g month:03 |g pages:552-558 |
856 | 4 | 0 | |u http://dx.doi.org/10.1093/jac/dkae001 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 79 |j 2024 |e 3 |b 01 |c 03 |h 552-558 |